​

Metagenomi (MGX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

MGX Stock Forecast

Metagenomi (MGX) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $14.50, with a high of $22.00 and a low of $7.00. This represents a 728.57% increase from the last price of $1.75.

- $5 $10 $15 $20 $25 High: $22 Avg: $14.5 Low: $7 Last Closed Price: $1.75

MGX Stock Rating

Metagenomi stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

MGX Price Target Upside V Benchmarks

TypeNameUpside
StockMetagenomi728.57%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$1.75$1.75$1.75
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25-41--5
Nov, 25141--6
Oct, 25141--6
Sep, 25151--7
Aug, 25241--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 21, 2024Mitchell KapoorH.C. Wainwright$7.00$3.30112.12%300.00%
Mar 28, 2024Maury RaycrofJefferies$22.00$11.0998.38%1157.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 14, 2025Wells FargoOverweightOverweighthold
Oct 15, 2024H.C. WainwrightBuyBuyhold
Sep 04, 2024Cowen & Co.BuyBuyhold
Aug 21, 2024H.C. WainwrightBuyBuyhold
May 07, 2024H.C. WainwrightBuyinitialise
Mar 28, 2024JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$-30 $-24 $-18 $-12 $-6 $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.82-----
Avg Forecast$-19.54$-2.48$-2.66$-2.38$-3.70$-3.60
High Forecast$-4.92$-2.19$-1.10$-0.22$-3.22$-0.70
Low Forecast$-28.61$-2.67$-3.80$-4.33$-4.18$-7.03
Surprise %-90.69%-----

Revenue Forecast

$0 $12M $24M $36M $48M $60M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$44.76M-----
Avg Forecast$44.68M$51.81M$34.11M$40.24M$10.00M$10.00M
High Forecast$47.30M$59.70M$55.86M$40.30M$17.33M$17.33M
Low Forecast$42.06M$46.44M$15.37M$40.18M$3.80M$3.80M
Surprise %0.17%-----

Net Income Forecast

$-2B $-1B $-900M $-600M $-300M $0 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-68.25M-----
Avg Forecast$-629.26M$-91.13M$-112.09M$-151.26M$-138.91M$-135.16M
High Forecast$-184.82M$-82.06M$-41.23M$-8.13M$-120.89M$-26.28M
Low Forecast$-1.07B$-100.21M$-142.70M$-162.54M$-156.94M$-263.89M
Surprise %-89.15%-----

MGX Forecast FAQ

Is Metagenomi stock a buy?

Metagenomi stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Metagenomi is a favorable investment for most analysts.

What is Metagenomi's price target?

Metagenomi's price target, set by 5 Wall Street analysts, averages $14.5 over the next 12 months. The price target range spans from $7 at the low end to $22 at the high end, suggesting a potential 728.57% change from the previous closing price of $1.75.

How does Metagenomi stock forecast compare to its benchmarks?

Metagenomi's stock forecast shows a 728.57% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Metagenomi over the past three months?

  • December 2025: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Metagenomi’s EPS forecast?

Metagenomi's average annual EPS forecast for its fiscal year ending in December 2024 is $-2.48, marking a 36.26% increase from the reported $-1.82 in 2023. Estimates for the following years are $-2.66 in 2025, $-2.38 in 2026, $-3.7 in 2027, and $-3.6 in 2028.

What is Metagenomi’s revenue forecast?

Metagenomi's average annual revenue forecast for its fiscal year ending in December 2024 is $51.81M, reflecting a 15.76% increase from the reported $44.76M in 2023. The forecast for 2025 is $34.11M, followed by $40.24M for 2026, $10M for 2027, and $10M for 2028.

What is Metagenomi’s net income forecast?

Metagenomi's net income forecast for the fiscal year ending in December 2024 stands at $-91.132M, representing an 33.52% increase from the reported $-68.255M in 2023. Projections indicate $-112M in 2025, $-151M in 2026, $-139M in 2027, and $-135M in 2028.